Our commitment to addressing serious #skindiseases is driven by a broad and deep pipeline. One way we are doing this is through the use of a PDE4 inhibitor, which helps restore balance to the immune system. Learn more below and check out our pipeline at https://bit.ly/4fRYXw3
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)
Biotechnology Research
Westlake Village, California 24,076 followers
Bioscience, applied to the skin.
About us
Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is an early commercial stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team’s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis' combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.
- Website
-
http://www.arcutis.com
External link for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Westlake Village, California
- Type
- Public Company
- Founded
- 2016
- Specialties
- Biotechnology, Medical Dermatology, Drug Development, Inflammation, Immunology, Clinical Trials, Topical Drugs, Bioscience, Commercialization, Plaque Psoriasis, Atopic Dermatitis, and Eczema
Locations
-
Primary
2945 Townsgate Rd
Westlake Village, California 91361, US
Employees at Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)
-
Jana Jarvis
Executive Director, Program Management at Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)
-
Frank Watanabe
-
Amanda Sheldon
Healthcare Communications Leader | Building Engagement through Storytelling | Digital & Social | Master Crafter
-
Ryan Souders
Associate General Counsel @ Arcutis Biotherapeutics, Inc. | DOJ Alum
Updates
-
The Arcutis team is having productive meetings and insightful discussions at #AAD2025! Come meet us at booth 1361 to throw some football passes for charity and talk to our team about how they are making meaningful innovations for people with serious #skindiseases. American Academy of Dermatology #clinicaldermatology #ArcutisAtAAD
-
We’re back at the 83rd annual meeting of the American Academy of Dermatology and look forward to sharing data from our studies for #atopicdermatitis and scalp and body #psoriasis. Learn more: https://lnkd.in/g-23jtJP #AAD2025 #clinicaldermatology #ArcutisAtAAD
-
This year’s #WomensHistoryMonth theme is “Moving Forward Together.” Some of the women of Arcutis shared words of encouragement to future generations. #ThisisArcutUS
-
Our Chief Medical Officer, Patrick Burnett, MD, PhD, is participating in a fireside chat at the TD Cowen Healthcare Conference today to share how we’re working hard at Arcutis to further meaningful innovation in serious #skindiseases. Join us via the webcast https://bit.ly/3EZ6P2a.
-
-
#NEWS: Today, we announced acceptance from the FDA of our application for our topical treatment for #atopicdermatitis for children ages 2 to 5. Learn more: https://bit.ly/3QABLrS $ARQT
-
-
#NEWS: Today, we announced 2024 #Q4 and full year financial results. Read our release for full results and other business updates: https://lnkd.in/g_GU-u3a $ARQT
-
-
#NEWS Pediatric Dermatology published positive results of our once daily roflumilast cream 0.05% in children with #atopicdermatitis aged 2 to 5 years from our Phase 3 #clinicaltrials. Read more: https://bit.ly/4ia96pq
-
-
This month we’re giving a shoutout to our Associate Director of Healthcare Compliance, Deirdre Kuzela, who’s been an integral member of our team for nearly three years. Thank you, Deirdre! #ThisisArcutUS #CompanyCulture
-
We are currently exploring the use of JAK1 inhibitors and their potential to treat serious #skindiseases like #alopeciaareata. Learn about JAK1 inhibitors below. https://www.arcutis.com/